Oxaliplatin is a third-generation platinum drug that belongs to the chemotherapy drugs for cancer treatment and is not a targeted drug. Oxaliplatin belongs to the chemotherapeutic drugs, can inhibit the replication and transcription of cellular DNA, with anti-tumor effects. Clinically, this product is used in combination with 5-fluorouracil and folinic acid in the first-line treatment of metastatic colorectal cancer, as well as in the adjuvant treatment of stage III colon cancer after complete resection of the primary tumor. Common adverse reactions to this product include diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, peripheral sensory neuropathy, etc. It is contraindicated in patients with known hypersensitivity to oxaliplatin or hypersensitivity to other platinum compounds, and in lactating women. This product needs to be used in the hospital by a physician, if obvious discomfort occurs after administration, please inform the physician promptly.